Overview of Volna-K

Property	Description
Active Ingredient	Diclofenac (as the Potassium salt)
Form	Solid Oral Dosage (Tablets or Capsules)
Pharmacological Class	Non-Steroidal Anti-Inflammatory Drug (NSAID)
Origin	Synthetic Compound
Common Use	Reduction of inflammation and pain relief

What Type of Medicine is Volna-K? (Definition and Classification)

Volna-K is a proprietary brand name for a medication classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID), a pharmacological group clinically recognized for its dual capacity to manage pain and inflammation. The sole active constituent is the synthetic compound Diclofenac, which is chemically defined as a benzeneacetic acid derivative. Diclofenac is globally recognized as a foundational medicine for pain and inflammation, and is included on the World Health Organization (WHO) Model List of Essential Medicines.

This classification indicates the drug's primary function is to target and reduce the underlying process of inflammation. This action is pharmacologically distinct from that of centrally acting pain relievers, targeting the peripheral mechanism of symptom development, thus offering a fundamental therapeutic purpose in managing discomfort arising from conditions like acute musculoskeletal strain.

What is the Composition and Form of Volna-K? (Composition and Physical Identity)

Volna-K is a single active ingredient product, distinguished by its formulation using the highly soluble Potassium salt (Diclofenac Potassium). This salt form is a defining feature of Volna-K, differentiating it from formulations containing the sodium salt or the free acid. This chemical structure is specifically engineered for rapid dissolution and oral administration as tablets or capsules, enabling enhanced systemic absorption. This rapid absorption profile is beneficial when treating acute conditions requiring prompt relief.

What is the General Benefit of Volna-K? (High-Level Purpose)

The general therapeutic purpose of Volna-K is to provide effective management of pain and reduction of physical swelling resulting from inflammatory processes. The mechanism involves intervening in the biological pathways that generate and transmit these symptoms. This means the medicine is systematically utilized to help calm the body's overactive inflammatory response, leading to broad, systemic relief from associated discomfort.

What side effects are possible with Volna-K?

Possible Side Effects and Safety Information

Volna-K (diclofenac potassium) is associated with officially documented risks and adverse reactions. The safety information is structured around Serious Warnings and dose-related restrictions mandated by regulatory authorities.

Serious Adverse Reactions

The most serious, potentially fatal risks documented in regulatory labeling are:

Cardiovascular Thrombotic Events: Non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk of serious cardiovascular events such as myocardial infarction (heart attack) and stroke, which can be fatal. This risk may occur early in treatment and may increase with higher doses and longer duration of use.
Gastrointestinal Events: NSAIDs carry a risk of serious, potentially fatal gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines. These events can occur at any time without warning symptoms.
Hepatotoxicity: Serious liver reactions, including fulminant hepatitis, liver failure, and liver necrosis, have been reported rarely and may be fatal.
Serious Skin Reactions: Rare, serious skin adverse events, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, have been reported.

Common and Other Adverse Reactions

Commonly reported side effects (occurring in ge 1/100 to < 1/10 of patients) often involve the gastrointestinal and nervous systems, including headache, dizziness, vertigo, nausea, vomiting, dyspepsia, abdominal pain, and rash. Other system-organ classes involved include: Blood and Lymphatic System Disorders, Cardiac Disorders (e.g., heart failure, hypertension), and Renal and Urinary Disorders (e.g., renal papillary necrosis, acute renal failure).

Contraindications and Restrictions

Contraindications include use for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery and use in the third trimester of pregnancy, due to risks to the fetus. The use of the lowest effective dose for the shortest duration possible is a key regulatory safety limitation to minimize the potential for cardiovascular and gastrointestinal risks.

Overdose and Emergency Response

Overdose of Volna-K (Diclofenac Potassium) may present with officially documented clinical manifestations, including common gastrointestinal symptoms such as nausea, vomiting, epigastric pain, and stomach pain. Central nervous system effects are also documented, encompassing headache, dizziness, and drowsiness.

Regulatory labeling emphasizes the potential for severe or life-threatening outcomes that require urgent intervention. These include critical gastrointestinal events, such as bleeding or perforation, which are potentially fatal. Systemic organ toxicity is a documented risk, specifically the development of Acute Renal Failure and Liver Failure. More severe CNS manifestations observed in high-exposure cases include Convulsions (seizures), Coma, and Respiratory depression.

Immediate medical attention must be sought for signs consistent with an Anaphylactic/Anaphylactoid Reaction or for any indication of the severe systemic effects mentioned above.

Regulatory documents state that no specific antidote is known for Volna-K overdose. Management is constrained to providing symptomatic and supportive treatment. Procedural options such as Activated charcoal or Gastric lavage may be considered for recent ingestion, and continued monitoring of renal and hepatic function is required. Official labeling notes that elderly patients and those with pre-existing organ impairment are at heightened risk for serious outcomes.

Therapeutic Uses of Volna-K

What Volna-K Treats: Main Uses and Benefits

Volna-K is commonly used when short-term symptomatic assistance is needed across conditions characterized by periods of heightened symptoms and involving the simultaneous presence of pain and inflammation. The medication may assist with managing acute or disruptive episodes.

Diclofenac potassium is relevant for easing symptoms in key therapeutic areas including Osteoarthritis, Rheumatoid Arthritis, Primary Dysmenorrhea, and general mild-to-moderate pain.

Therapeutic Relief and Comfort

This medication is commonly used to help with symptoms related to inflammatory or irritative states, such as pain, stiffness, and physical swelling that may become more disruptive during flare-ups. It is applied during phases of increased distress or discomfort. The medication may be part of symptomatic management during the acute, disruptive phase of symptoms, such as the cyclical pain of menstrual cramps or an acute migraine attack. This assistance can help with maintaining functional stability when symptoms interfere with routine activities and supports patients during episodes of heightened discomfort.

Quick Fact: Relief for Acute Symptomatic Episodes Volna-K may be part of symptomatic management when short-term symptomatic assistance is appropriate for sudden or episodic pain and swelling, assisting with maintaining functional stability during temporary physiological imbalance.

Regulatory References

DailyMed drug label managed by the U.S. National Library of Medicine

Eligibility and Restrictions for Use

Volna-K (which contains diclofenac) is strictly contraindicated and must not be used by specific populations, as defined by official regulatory documents.

Populations Who Must Not Use Volna-K

Classification	Exclusion Criteria (Must Not Use)
Hypersensitivity	Individuals with a known allergy to diclofenac, any component of the medication, or a history of allergic-type reactions (e.g., asthma, urticaria) after taking Aspirin or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs).
Surgical Setting	Patients undergoing treatment for pain immediately before or after Coronary Artery Bypass Graft (CABG) surgery.
Pregnancy Stage	Women who are 30 weeks gestation or later (third trimester) due to the risk of premature closure of the fetal ductus arteriosus.

Populations Requiring Extreme Caution or Restriction

Individuals who possess certain pre-existing conditions or are within vulnerable age groups may be restricted from use or require close monitoring:

Cardiovascular Disease: Patients with established cardiovascular disease, uncontrolled hypertension, or a history of recent myocardial infarction (heart attack) should avoid use, especially at high doses or for prolonged periods, as this increases the risk of serious thrombotic events.
Gastrointestinal Risk: Patients with a history of active or recurrent gastrointestinal (GI) bleeding, ulceration, or perforation are at greater risk for serious, potentially fatal GI events, and should use the medication only if the lowest effective dose can be used for the shortest possible duration.
Renal or Hepatic Impairment: Patients with advanced renal disease or severe hepatic impairment are generally advised to avoid Volna-K. The elderly are also at increased risk for serious GI, renal, and cardiovascular effects and require cautious use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents describe several clinically significant interactions for Volna-K that require specific patient monitoring or product restrictions when co-administered.

Documented Interaction Categories

The following classes of medicines have documented interactions with Volna-K, primarily increasing the risk of adverse effects or reducing the efficacy of the co-administered drug:

Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Concomitant use is generally discouraged due to an increased risk of serious gastrointestinal and renal adverse effects.
Drugs that Interfere with Hemostasis: This includes Anticoagulants (such as Warfarin), Antiplatelets (including Aspirin at analgesic doses), and SSRIs/SNRIs. Co-administration significantly increases the risk of bleeding, requiring careful patient monitoring.
Antihypertensive Agents and Diuretics: Volna-K may diminish the blood pressure-lowering effect of agents like ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), and Beta-Blockers. It may also reduce the natriuretic effect of Diuretics.
Medicines with Narrow Therapeutic Windows: The drug can increase the serum concentrations of substances such as Digoxin and Lithium, which necessitates serum level monitoring to prevent toxicity.

Procedural and Restriction Notes

Specific constraints include avoiding use with other NSAIDs and the need for intensified monitoring of blood pressure and renal function when combined with antihypertensive medicines. Furthermore, the combination with Voriconazole (a potent enzyme inhibitor) significantly increases the drug's exposure in the body.

Mechanism of Action

How Volna-K Works

Volna-K's mechanism centers on acting as a critical cofactor for the enzyme Gamma-Glutamyl Carboxylase (GGCX) within hepatic cells. This interaction facilitates the necessary post-translational modification of specific inactive coagulation factor precursors (Factors II, VII, IX, and X).

The primary molecular event is gamma-carboxylation, which chemically modifies the factor precursors, equipping them with gamma-carboxyglutamate (Gla) residues. This modification is essential as it grants the coagulation factors the ability to efficiently bind circulating calcium ions ( Ca^2+).

Furthermore, Volna-K supports the continuous Vitamin K cycle by supplying substrate to Vitamin K Epoxide Reductase (VKOR), which recycles the consumed cofactor. This sustained recycling ensures a consistent supply of factors ready for secretion. The systemic consequence of these molecular events is the acceleration of the final coagulation cascade at injury sites, leading to the formation of a fibrin clot.

Dosage and Administration Information

How to Use Volna-K: Official Administration Guidelines

Volna-K, which contains Diclofenac Potassium, is administered exclusively through the oral route as an immediate-release solid dosage form. The medication is engineered for rapid dissolution and systemic absorption, supporting its use in conditions requiring prompt symptomatic assistance.

Standard Dosage and Frequency

Usage follows the principle of employing the lowest effective dosage for the shortest duration necessary for relief. The typical adult dosing regimen for acute pain is 50 mg, which may be taken up to three times daily. Doses are typically divided throughout the day, and the overall total daily intake is generally limited, not to exceed 150 mg. Administration may be scheduled or taken on an as-needed (PRN) basis during periods of acute symptoms.

Contextual Use and Administration

Volna-K may be taken with or without food. While food does not significantly impact the total amount of medicine absorbed, administration with food may delay the onset of relief. A critical procedural constraint is the avoidance of concurrent use: this medication should not be administered at the same time as other non-steroidal anti-inflammatory drugs (NSAIDs).

Population-Specific Usage Rules

Official labeling includes specific administration rules for certain populations. For older adults, the use of the lowest possible effective dosage is mandated. Patients with mild to moderate renal impairment typically require no dose adjustment. However, those with hepatic disease may require dose reduction due to the drug's metabolic profile. The safety and efficacy of Volna-K have not been established in the pediatric population.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Volna-K

Evidence for Use in Acute Pain and Symptom Episodes

Research has primarily been conducted using single-dose randomized controlled trials applied in studies examining patient-reported experiences of pain. Volna-K was studied for conditions associated with acute or disruptive episodes, such as pain following dental procedures. The outcomes measured included patient-reported outcomes describing perceived discomfort and the time it took for the first noticeable change in symptoms to be recorded.

The findings describe patterns observed in the studies regarding how pain intensity was recorded over the course of the first few hours. The vast majority of the high-quality data is structured around single-dose evaluation of outcomes. The follow-up durations were limited, and research is concentrated on short follow-up periods; evidence for outcomes beyond a few days is limited.

Evidence for Use in Primary Dysmenorrhea

Volna-K was evaluated in studies focusing on episodes where symptoms become more noticeable, specifically addressing conditions characterized by fluctuating or episodic manifestations like primary dysmenorrhea. Research examined changes in outcomes related to physical discomfort during periods of heightened symptom activity. Research describes the changes measured in symptom intensity and patterns related to the reported level of functional imbalance during the observed cycle.

However, the evidence quality varies across studies, and most research explores short-term symptom changes over defined time intervals related to a single menstrual cycle. Long-term outcomes for continuous use over many cycles are not fully characterized.

Evidence for Use in Symptomatic Management of Osteoarthritis and Rheumatoid Arthritis

The active ingredient in Volna-K was studied for conditions marked by functional limitations, such as symptomatic management of pain and stiffness related to Osteoarthritis (OA) and Rheumatoid Arthritis (RA). Researchers utilized intermediate-term randomized controlled trials that focused on outcomes related to systemic or functional imbalance over periods typically spanning a few weeks to a few months.

Data show patterns related to changes in joint-related physical discomfort and functional assessments. While a body of evidence exists, the follow-up durations were limited when considering the long-term nature of these conditions. Long-term outcomes for continuous use in chronic conditions are not fully established based on the trials for this specific rapid-acting formulation.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Volna-K (FAQ)

Q: How quickly should I expect Volna-K to start working?

Volna-K is the potassium salt formulation, which official documents state is designed for rapid absorption. Official documents report that mean peak concentrations of the medicine in the blood were typically observed within 30 to 54 minutes after being taken in clinical studies.

Q: What should I do if a side effect seems serious?

Official instructions advise patients to immediately report symptoms of serious events, such as chest pain, slurring of speech, or signs of liver injury, to their healthcare provider. Official instructions also advise patients to seek immediate emergency help if they experience symptoms of an anaphylactic (severe allergic) reaction.

Q: Can Volna-K be taken with vitamins or herbal supplements?

Regulatory documents advise caution when using Volna-K with other medicines that interfere with blood clotting, or hemostasis. Official documents state that individuals should disclose all supplements, including herbals and vitamins, to a healthcare professional before use.

Q: What are the long-term effects of taking Volna-K?

Regulatory documents note that the risk of serious side effects, specifically cardiovascular and gastrointestinal events, may increase with the duration of use. Evidence from clinical trials is concentrated on short follow-up periods, and long-term outcomes for continuous use have not been fully characterized in the studies conducted.

Q: Can Volna-K affect my blood pressure?

Yes, official regulatory documents state that Volna-K, like other medicines in its class, may lead to the onset of new hypertension or the worsening of existing high blood pressure. Official labeling indicates that blood pressure should be monitored closely during treatment.

Q: Is it necessary to have routine blood work while taking Volna-K?

For patients on long-term treatment, regulatory guidance states that periodic monitoring of a Complete Blood Count (CBC) and a chemistry profile may be considered. This is due to the potential for serious gastrointestinal bleeding, liver problems, and kidney injury.

Q: How does Volna-K compare to a placebo in studies?

Clinical trial findings describe that the drug demonstrated a specific level of pain relief in comparison to a placebo in acute pain settings. Volna-K is studied as a treatment to help calm the body's overactive inflammatory response.

Q: Is Volna-K considered a first-line treatment?

Volna-K's active ingredient is included on the World Health Organization (WHO) Model List of Essential Medicines. This designation recognizes the drug's established role as a foundational medicine for managing pain and inflammation globally.

Q: How is Volna-K generally eliminated from the body?

The drug is eliminated from the body primarily through a process of metabolism in the liver. This process is followed by the subsequent excretion of the metabolic compounds via the urine and bile.

Q: What does the official labeling say about taking Volna-K with food?

Official labeling states that Volna-K may be taken with or without food. However, regulatory documents note that administration with food may delay the onset of relief.

Q: Is Volna-K known to cause weight gain?

Official information advises patients to be alert for symptoms of fluid retention, including unexplained weight gain. Official information advises patients to contact their healthcare provider if symptoms like unexplained weight gain occur, as this relates to the medication's effects on fluid balance.

Q: Does Volna-K affect sleep?

Yes, the official product information reports that adverse reactions affecting the nervous system have been observed in clinical trials. These reported effects include both difficulty sleeping (insomnia) and drowsiness.

Q: Are there different strengths of Volna-K available?

Regulatory documents describe the active ingredient is supplied in multiple strengths for oral use. These typically include 25 mg and 50 mg solid oral dosage forms.

Q: Can I drive or operate machinery while using Volna-K?

Since the medication may cause adverse reactions such as dizziness, drowsiness, and vertigo, official information advises patients to exercise caution when driving or operating machinery.

Q: Is Volna-K gluten-free or lactose-free?

Regulatory documents describe Diclofenac potassium tablets as containing lactose monohydrate among the inactive ingredients. Official labeling specifies that information on gluten content is not provided.

Q: Does Volna-K have a black box warning from the FDA?

Yes, Volna-K's active ingredient is subject to a BOXED WARNING (also called a Black Box Warning) by the FDA. This is the strongest warning required by the FDA to call attention to the risks of serious cardiovascular and gastrointestinal adverse events.

Q: Is Volna-K commonly used in other countries besides the US?

The drug's active ingredient is included on the World Health Organization (WHO) Model List of Essential Medicines. This global recognition indicates it is considered a widely used and necessary treatment.

Q: Does Volna-K cause dizziness?

Yes, dizziness is listed in official documents as one of the commonly reported side effects. This means it has been reported to occur in 1 to 10 out of every 100 patients.

Q: Is there a risk of dependency with Volna-K?

Official regulatory information describes the active ingredient as a Non-Steroidal Anti-Inflammatory Drug (NSAID). The medication is not classified as a controlled substance and therefore does not have a recognized potential for physical dependency.

Q: Is it normal to feel nausea when first starting Volna-K?

Nausea is listed in official documents as one of the commonly reported side effects that often involves the gastrointestinal system. Common adverse reactions are those that occur in 1 to 10 out of every 100 patients.

Q: Why is Volna-K only available by prescription?

Volna-K is available by prescription only because its drug class carries a potential for serious side effects, including cardiovascular and gastrointestinal events. This mandates medical supervision to ensure its safe and effective use.

Q: Does Volna-K have a potential for abuse?

Official regulatory information describes the active ingredient as a Non-Steroidal Anti-Inflammatory Drug (NSAID). It is not classified as a controlled substance and, as such, has no recognized potential for abuse.

Q: Is Volna-K a controlled substance?

Volna-K is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID) and is not listed as a controlled substance under federal regulation.

Q: What makes Volna-K different from its generic version?

Volna-K is a proprietary brand name for the potassium salt of diclofenac. Official regulatory descriptions highlight this salt is formulated for rapid dissolution and systemic absorption, which is distinct from the more slowly absorbed sodium salt formulations.

Q: Are there any known interactions between Volna-K and alcohol?

Official regulatory warnings note that the risk of serious gastrointestinal adverse events is increased for certain patients, including those with a history of ulcers, who smoke, or who use alcohol. Alcohol use is a recognized risk factor that increases the risk of serious gastrointestinal adverse events.

Q: How does Volna-K affect mood or anxiety?

Official documents list adverse reactions reported in the nervous system that include effects such as anxiety, confusion, and depression. Individuals who notice changes in mood while taking the medication should inform their healthcare provider.

Q: Is Volna-K appropriate for adolescents?

Official regulatory documents indicate that the safety and efficacy of Volna-K have not been established in the pediatric population.

How should Volna-K be stored and disposed of?

Storage and Disposal Requirements for Volna-K

Storage and disposal of Volna-K (diclofenac potassium) must adhere strictly to the conditions documented in official regulatory labeling to ensure product integrity and safety.

Required Storage Conditions

Requirement	Constraint
Temperature	Do not store above 30 C.
Protection	Store in the original package and protect from moisture.
Child Safety	Must be kept out of the reach of children.

Official Disposal Instructions

Unused or expired tablets must be disposed of according to official guidance to prevent environmental release. Disposal of the contents and container must be done at an authorized hazardous or special waste collection point, in accordance with local, national, and international regulations.

Volna-K